Articles tagged "Pharmacokinetics"

2021 American Transplant Congress
Tacrolimus Therapeutic Exposure is Not Consistently Predicted by Target Troughs or CYP3A5 Variants in Stable Renal Transplant Recipients
K. Tornatore¹, K. Attwood², D. Brazeau³, B. Murray⁴
¹Pharmacy Practice, School of Pharmacy; University at Buffalo, Buffalo, NY, ²Biostatistics, School of Public Health; University at Buffalo, Buffalo, NY, ³Pharmacy Practice, School of Pharmacy; Marshall University, Huntington, WV, ⁴Medicine, Erie County Medical Center Corp., Buffalo, NY
*Purpose: Tacrolimus (TAC) immunosuppression requires therapeutic trough monitoring post-transplant due to notable interpatient pharmacokinetic(PK) variability which may be attributed to CYP3A5 polymorphisms. We investigated the…
2021 American Transplant Congress
Belatacept Exposure Not Associated With Rejection. Can Doses be Lowered without Compromising Efficacy?
M. McGowan¹, A. Bickenbach¹, B. Miyagawa², A. Christianson¹, T. Mizuno², P. West-Thielke³, J. Leone⁴, E. Woodle¹, D. Kaufman⁵, A. Wiseman⁶, A. Matas⁷, A. Vinks², R. Alloway¹
¹U Cincinnati, Cincinnati, OH, ²Cincinnati Children's Med Center, Cincinnati, OH, ³U Illinois, Chicago, IL, ⁴Tampa Gen, Tampa, FL, ⁵U Wisconsin, Madison, OH, ⁶Centura Transplant, Denver, CO, ⁷U Minnesota, Minneapolis, MN
*Purpose: Phase 1 and 2 belatacept(BELA) pharmacokinetic(PK) studies informed dosing in phase 3 studies. PK data from these studies revealed higher BELA troughs on Day…
2021 American Transplant Congress
Evaluation of Conversion to Extended-Release Tacrolimus in Abdominal Organ and Thoracic Transplant Recipients
A. Diamond¹, N. Agarwal², A. Younas², N. Sifontis², J. Au¹, C. Ruggia-Check¹
¹Pharmacy, Temple University Hospital, Philadelphia, PA, ²Pharmacy, Temple University School of Pharmacy, Philadelphia, PA
*Purpose: An established approach for conversion from immediate-release tacrolimus (IR TAC) to extended-release tacrolimus (LCPT) in kidney transplantation exists, but is lacking in other organ…
2021 American Transplant Congress
Avoiding Tacrolimus Under- and Overexposure with a Dosing Algorithm for Renal Transplant Recipients: A Single Arm Prospective Intervention Trial
M. I. Francke¹, L. M. Andrews², H. L. Le², J. van de Wetering¹, M. C. Clahsen-van Groningen³, T. van Gelder⁴, R. H. van Schaik⁵, B. van der Holt⁶, B. C. de Winter², D. A. Hesselink¹
¹Internal medicine, nephrology and transplantation, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ²Hospital Pharmacy, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ³Pathology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁴Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, Netherlands, ⁵Clinical Chemistry, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁶Hematology, Erasmus MC, University Medical Center, Rotterdam, Netherlands
*Purpose: Bodyweight-based tacrolimus dosing followed by therapeutic drug monitoring is standard clinical care after renal transplantation. However, after transplantation, a meagre 38% of patients is…
2021 American Transplant Congress
Evaluation of Empiric Extended-Release Tacrolimus Dosing in Adult Kidney Transplant Recipients
C. Patel, S. Lee, D. M. Salerno, N. W. Lange, J. Hedvat
Pharmacy, NewYork-Presbyterian Hospital, New York, NY
*Purpose: Envarsus XR® (extended-release [XR] tacrolimus) is the standard of care tacrolimus formulation at our center for de novo maintenance immunosuppression in adult kidney transplant…
2021 American Transplant Congress
Quantifying the Interaction Between Posaconazole and Tacrolimus in Liver Transplant Recipients: A Practical Approach
B. Lane¹, U. Kaszubski¹, A. Freeman¹, B. Wise¹, L. Hutchinson¹, M. Janusek¹, G. Therapondos², H. Bohorquez³, S. Anders¹
¹Pharmacy, Ochsner Medical Center, New Orleans, LA, ²Hepatology, Ochsner Medical Center, New Orleans, LA, ³Transplant Surgery, Ochsner Medical Center, New Orleans, LA
*Purpose: The interaction between tacrolimus (FK) and posaconazole (POSA) is well documented, however the extent of this interaction and the practical management has yet to…
2021 American Transplant Congress
Therapeutic Enoxaparin Dosing in Lung Transplant Recipients
S. Finder, M. Morrison, K. B. Harrison, S. A. Heeney
Vanderbilt University Medical Center, Nashville, TN
*Purpose: Enoxaparin 1 mg/kg subcutaneously every 12 hours for therapeutic anticoagulation is known to increase rates of supratherapeutic anti-Xa levels in lung transplant recipients (LTRs).…
2021 American Transplant Congress
Evaluate the Effect of Cresemba (isavuconazonium Sulfate) Capsule and Noxafil (posaconazole) Delayed Release Tablets on Tacrolimus Dose to Concentration (D/C) Ratios in Lung Transplant Recipients
H. Sweiss¹, E. Kincaide¹, D. Levine², R. Hall¹
¹University Health, San Antonio, Department of Pharmacotherapy and Pharmacy Services, The University of Texas at Austin, Pharmacotherapy Division, College of Pharmacy, San Antonio, TX, ²University Health, San Antonio, University of Texas Health Science Center at San Antonio, San Antonio, TX
*Purpose: Evaluate the effect of Cresemba (isavuconazonium sulfate) capsule and Noxafil (posaconazole) delayed release tablet on tacrolimus dose to concentration (D/C) ratio in lung transplant.*Methods:…
2020 American Transplant Congress
Belatacept Removal by Plasmapheresis: Kinetics, Dose Adjustments and Clinical Recommendations
S. Tremblay¹, N. Wilson¹, B. Miyagawa², H. Kuzaro¹, A. R. Shields³, R. R. Alloway¹, A. Govil¹, J. Kremer⁴, E. Woodle¹, T. Mizuno², A. A. Vinks²
¹U Cincinnati, Cincinnati, OH, ²Cincinnati Children's, Cincinnati, OH, ³U Cincinnati / Christ Hospital, Cincinnati, OH, ⁴Christ Hospital, Cincinnati, OH
*Purpose: Belatacept (BELA), a protein immunosuppressant, has limited available pharmacokinetic (PK) data. Available PK data, limited to product development analyses, shows moderate intrapatient variability with…
2020 American Transplant Congress
Largest Experience of Safety, and Efficacy of Patiromer in Solid Organ Transplants (SOT)
P. Singh¹, H. Winters², T. E. Pesavento¹, K. Schnelle²
¹Transplant Nephrology, Ohio State University, Columbus, OH, ²Transplant Pharmacy, Ohio State University, Columbus, OH
*Purpose: Hyperkalemia, a potentially life‐threatening electrolyte abnormality, is commonly seen SOT. The predisposing factors are renal-dysfunction, and medications (CNI, TMP-SMX, ACEI, and ARBs). Patiromer, a…